BROWSE BY
0
argenx SE Banner Image

argenx SE has reached its limit for free report views

Work for argenx SE? Upgrade Your Profile and unlock all your responsibility reports.

Upgrade Profile

argenx SE

  • Ticker ARGX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
argenx SE Logo Image
  • 501-1000 Employees
  • Based in Ghent, Belgium
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious…More autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States and Japan.
Visit website
argenx SE

Most Recent Responsibility Report

argenx SE
MOST RECENT 2021 Environmental, Social and Governance Report

Report Locked. argenx SE has reached its limit for free report views.

View Annual Report

This company has an annual report available to view on our partner site, AnnualReports.com

Our service enables potential investors to review the most recent and archived argenx SE Sustainability Report, argenx SE Corporate Social Responsibility Report, argenx SE CSR Report, argenx SE Corporate Responsibility, argenx SE CR Report, argenx SE Citizenship Report, argenx SE ESG Report, and argenx SE Environmental Report online.